Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

  • Hiroaki Kanzaki
  • , Yujin Hoshida

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e121-e122
JournalClinical and Molecular Hepatology
Volume31
Issue number1
DOIs
StatePublished - Jan 2025
Externally publishedYes

Keywords

  • Hepatocellular carcinoma
  • Immunotherapy
  • Predictive biomarker
  • Tumor immune microenvironment

Cite this